The outcome of haemopoietic stem cell transplantation in the treatment of lymphoplasmacytic lymphoma in the UK: a British Society Bone Marrow Transplantation study

References

• NCCN practice guidelines for multiple myeloma. National Comprehensive Cancer Network. Oncology (Huntingt) 1998; 12: 317–351.
   PubMedGoogle Scholar
• Anon. A clinical evaluation of the International Lymphoma StudyGroup classification of non-Hodgkins lymphoma. The Non-Hodgkins Lymphoma Classification Project. Blood 1997; 89: 3909–3918.
   PubMed Web of Science ®Google Scholar
• Gertz MA. Waldenstrom's macroglobulinemia: a review of therapy. Leuk Lymphoma 2002; 43: 1517–1526.
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Witzig TE. Waldenstrom macroglobulinemia. Curr Treat Options Oncol 2004; 5: 239–247.
   PubMedGoogle Scholar
• Johnson SA, Oscier DG, Leblond V. Waldenstrom's macroglobu-linaemia. Blood Rev 2002; 16: 175–184.
   PubMedGoogle Scholar
• Dimopoulos MA, Panayiotidis P, Moulopoulos LA, Sfikakis P, Dalakas M. Waldenstrom's macroglobulinemia: clinical features, complications, and management. J Clin Oncol 2000; 18: 214–226.
   PubMed Web of Science ®Google Scholar
• UK CSLG, France GCLM, Germany CSG, Australasia LLG. A randomised trial of chlorambucil versus fludarabine as initial therapy of Waldenstroms's macroglobulinaemia and splenic lymphoma with villous lymphocytes. Available at: http://www.waldenstroms.org, 2005.
   Google Scholar
• Gertz MA, Anagnostopoulos A, Anderson K et al. Treatment recommendations in Waldenstrom's macroglobulinemia: consen-sus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003; 30: 121–126.
   PubMed Web of Science ®Google Scholar
• Desikan R, Li Z, Jagannath S. Waldenstrom's macroglobulinae-mia: current therapy and future approaches. BioDrugs 2002; 16: 201–207.
   PubMed Web of Science ®Google Scholar
• Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Pathology and genetics of tumours of haematopoietic and lymphoid tissue. Lyon: IARC Press, 2001.
   Google Scholar
• Durrant IJ, Prentice HG, Richards SM. Intensification of treatment for adults with acute lymphoblastic leukaemia: results of U.K. Medical Research Council randomized trial UKALL XA. Medical Research Council Working Party on Leukaemia in Adults. Br J Haematol 1997; 99: 84–92.
   PubMed Web of Science ®Google Scholar
• Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295–304.
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Weisdorf D, Martin P et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825–828.
   PubMed Web of Science ®Google Scholar
• van Os R, Robinson S, Sheridan T, Mislow JMK, Dawes D, Mauch PM. Granulocyte colony-stimulating factor enhances bone marrow stem cell damage caused by repeated administration of cytotoxic agents. Blood 1998; 92: 1950–1956.
   PubMed Web of Science ®Google Scholar
• Dreger P, Kloss M, Petersen B et al. Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood 1995; 86: 3970–3978.
   PubMed Web of Science ®Google Scholar
• Boccadoro M, Palumbo A, Bringhen S et al. Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma. Haematologica 2002; 87: 846–850.
   PubMed Web of Science ®Google Scholar
• Desikan R, Dhodapkar M, Siegel D et al. High-dose therapy with autologous haemopoietic stem cell support for Waldenstrom's macroglobulinaemia. Br J Haematol 1999; 105: 993–996.
   PubMed Web of Science ®Google Scholar
• Munshi NC, Barlogie B. Role for high-dose therapy with autologous hematopoietic stem cell support in Waldenstrom's macroglobulinemia. Semin Oncol 2003; 30: 282–285.
   PubMed Web of Science ®Google Scholar
• Yang L, Wen B, Li H et al. Autologous peripheral blood stem cell transplantation for Waldenstrom's macroglobulinemia. Bone Marrow Transplant 1999; 24: 929–930.
   PubMed Web of Science ®Google Scholar
• Dreger P, Glass B, Kuse R et al. Myeloablative radiochemotherapy followed by reinfusion of purged autologous stem cells for Waldenstrom's macroglobulinaemia. Br J Haematol 1999; 106: 115–118.
   PubMed Web of Science ®Google Scholar
• Anagnostopoulos A, Giralt S. Stem cell transplantation (SCT) for Waldenstrom's macroglobulinemia (WM). Bone Marrow Transplant 2002; 29: 943–937.
   PubMed Web of Science ®Google Scholar
• Lahuerta ii, Martinez-Lopez J, Serna JD et al. Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. Br J Haematol 2000; 109: 438–446.
   PubMed Web of Science ®Google Scholar
• Brown JR, Yeckes H, Friedberg JW et al. Increasing incidence of late second malignancies after conditioning with cyclophospha-mide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma J Clin Oncol 2005; 23: 2208–2214.
   PubMed Web of Science ®Google Scholar
• Madan R, Chang V, Yook C. Waldenstrom macroglobulinaemia evolving into acute lymphoblastic leukemia: a case report and a review of the literature. Leukemia 2003; 18: 1433–1435.
   Web of Science ®Google Scholar
• Micallef IN, Lillington DM, Apostolidis J et al. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol 2000; 18: 947–955.
   PubMed Web of Science ®Google Scholar
• Hosing C, Munsell M, Yazji S et al. Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma. Ann Oncol 2002; 13: 450–459.
   PubMed Web of Science ®Google Scholar
• Milligan DW, Kochethu G, Dearden C, Matutes E, MacConkey C, Catovsky D. High incidence of myelodysplasia and secondary leukaemia in the UK Medical Research Council Pilot of autografting in chronic lymphocytic leukaemia. Br J Haematol 2006; 133: 173–175.
   PubMed Web of Science ®Google Scholar
• Leone G, Voso MT, Sica S, Morosetti R, Pagano L. Therapy related leukemias: susceptibility, prevention and treatment. Leuk Lymphoma 2001; 41: 255–276.
   PubMed Web of Science ®Google Scholar
• Sorror ML, Mans MB, Storb R et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912–2919.
   PubMed Web of Science ®Google Scholar
• Parimon T, Au DH, Martin PJ, Chien JW. A risk score for mortality after allogeneic hematopoietic cell transplantation. Ann Intern Med 2006; 144: 407–414.
   PubMed Web of Science ®Google Scholar
• Ueda T, Hatanaka K, Kosugi S, Kishino BI, Tamaki T. Success-ful non-myeloablative allogeneic peripheral blood stem cell transplantation (PBSCT) for Waldenstrom's macroglobulinemia with severe pancytopenia. Bone Marrow Transplant 2001; 28: 609–611.
   PubMed Web of Science ®Google Scholar
• Tournilhac O, Leblond V, Tabrizi R et al. Transplantation in Waldenstrom's macroglobulinemia — the French experience. Semin Oncol 2003; 30: 291–296.
   PubMed Web of Science ®Google Scholar
• Anagnostopoulos A, Dimopoulos MA, Aleman A et al. High-dose chemotherapy followed by stem cell transplantation in patients with resistant Waldenstrom's macroglobulinemia. Bone Marrow Transplant 2001; 27: 1027–1029.
   PubMed Web of Science ®Google Scholar
• Anagnostopoulos A, Hari PN, Perez WS et al. Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia. Biol Blood Marrow Transplant 2006; 12: 845–854.
   PubMed Web of Science ®Google Scholar
• van Besien K, Rowlings PA, Murphy SC et al. Allogeneic bone marrow transplantation for low-grade lymphoma. Blood 1998; 92: 1832–1836.
   PubMed Web of Science ®Google Scholar
• Kim DH, Won DI, Lee NY, Sohn SK, Suh JS, Lee KB. Non-CD34(+ ) Cells, especially CD8(+) cytotoxic T cells and CD56(+ ) natural killer cells, rather than CD34 cells, predict early engraft-ment and better transplantation outcomes in patients with hematologic malignancies after allogeneic peripheral stem cell transplantation. Biol Blood Marrow Transplant 2006; 2: 719–728.
   Google Scholar
• Niederwieser D, Mans M, Shizuru JA et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unre-lated donors and postgrafting immunosuppression with cyclospor-ine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003; 101: 1620–1629.
   PubMed Web of Science ®Google Scholar
• Gopal AK, Pagel JM, Rajendran JG et al. Improving the efficacy of reduced intensity allogeneic transplantation for lymphoma using radioimmunotherapy. Biol Blood Marrow Transplant 2006; 12: 697–702.
   PubMed Web of Science ®Google Scholar